Delonix Bioworks and WuXi Vaccines Form Strategic Partnership to Accelerate Global Application of Innovative OMV Vaccine TechnologyOn April 21st, 2025, Delonix Bioworks, a global pioneer in innovative bacterial vaccine development, and WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), today announced a strategic partnership. Through the collaboration, Delonix Bioworks will leverage WuXi Vaccines' integrated development and manufacturing capabilities as well as the world-class quality system to advance its next-generation engineered Outer Membrane Vesicle (OMV) technology platform, OMV Plus, driving its widespread adoption for bacterial vaccines. Together, the companies will jointly facilitate innovation in bacterial vaccines, contributing to the protection of public health worldwide.Engineered OMV represents the most promising next-generation bacterial vaccine technology. As natural nanovesicles released by gram-negative bacteria, OMVs carry numerous bacterial antigens—including proteins and polysaccharides—which effectively solves the challenge of screening optimal antigens for bacterial vaccines. And their commercial applications have been validated in the market. Additionally, OMVs contain rich pathogen-associated molecular patterns (PAMPs), providing a built-in adjuvant effect that enhances vaccine potency without requiring additional adjuvants. Pathogen genome editing is crucial for OMV vaccine applications as it eliminates safety concerns such as endogenous pyrogens while significantly increasing yield and coverage. This technology enables vaccine development for the majority of gram-negative bacteria.Delonix Bioworks launched its OMV Plus platform in 2023, overcoming key technical bottlenecks in traditional OMV design and production through its leading pathogen genome editing technology. This breakthrough significantly enhanced vaccine safety and efficacy while reducing production costs. Through collaboration with WuXi Vaccines, the company achieved GMP-scale production of engineered OMV vaccines within 10 months, reaching over 1 million doses per 100L fermentation batch at less than $1 per dose—establishing a strong foundation for expanding the strategic partnership between the two companies.Dr. Qiubin Lin, founder and CEO of Delonix Bioworks"We are delighted to announce the strategic partnership with WuXi Vaccines, aimed at accelerating global access to novel bacterial vaccine technologies. After a year of intensive collaboration, marked by dedicated efforts and innovative approaches from both teams, we have combined Delonix Bioworks' robust vaccine innovation capabilities with WuXi Vaccines' in-depth know-how and expertise in vaccine CMC and manufacturing to achieve a landmark milestone – successfully scaling up the production of China's first MenB OMV vaccine at an unprecedented pace. This partnership not only enables significant improvements in productivity and manufacturing cost reduction, but also underscores Delonix Bioworks’ global leadership in pathogen genome capabilities and our shared commitment to enhancing the accessibility of novel bacterial vaccines."Mr. Jian Dong, CEO of WuXi Vaccines"We sincerely appreciate Delonix Bioworks’ longstanding trust in us. This strategic collaboration reaffirms WuXi Vaccines' value in expediting innovative vaccine development through our integrated platforms that uphold the utmost quality standards. Through this collaboration, both parties will fully leverage our combined strengths in OMV vaccine R&D, process development, and large-scale manufacturing to accelerate the research and commercialization of innovative bacterial vaccines for a broader range of global partners. WuXi Vaccines remains committed to meeting the growing demand for vaccine development and manufacturing services with our profound expertise and comprehensive end-to-end solutions, thereby improving the accessibility and affordability of vaccines worldwide to protect public health."About Delonix Bioworks Delonix Bioworks is a leading biotech pioneering innovative bacterial vaccine development, transforming the field from empirical approaches to rational design. Founded by pioneers in synthetic biology and vaccinology, we have developed comprehensive genome editing toolkits for over 15 pathogens and established multiple proprietary vaccine technology platforms. Our flagship OMV Plus platform is a state-of-the-art engineered technology that produces OMV vaccine candidates with enhanced efficacy and safety profiles. It enables scalable, cost-effective production and significantly accelerates the development timeline. This platform powers our Meningococcal Group B vaccine candidate, which shows best-in-class profiles and is approaching IND submission in 2025.Delonix Bioworks has won multiple awards in China and globally, including the Champion in Boehringer Ingelheim Innovation Prize. For more information, please visit https://delonixbio.com/About WuXi Vaccines WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, is a leading contract development and manufacturing organization (CDMO) that focuses on vaccine and preventive antibody’s development and manufacturing. It provides world-class, integrated development and manufacturing platforms to expedite partners’ vaccines to the clinical stage and the market, regardless of the vaccine modality (i.e., recombinant protein, viral, viral vectored, VLP, OMV, nucleic acid, conjugated vaccines). With its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (cell culture, viral, microbial, polysaccharide and protein conjugation), and extensive GMP manufacturing capacities, WuXi Vaccines provides an end-to-end service – from vaccine development to large-scale commercial production and distribution. The company can enable global clients to deliver critical vaccines anywhere in the world, making it an essential partner in protecting public health.For more information about WuXi Vaccines, please visit: https://wuxivaccines.com